Greenland Mines Ltd (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company's Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines' Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.
The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis ("ALS") and other neuromuscular disorders. This patent grant is a significant milestone for Greenland Mines as it expands the geographic protection of its Klotho gene therapy platform, which is central to the company's biotech strategy. The platform aims to address unmet medical needs in neuromuscular diseases, where current treatment options are limited.
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and Biotech, including Klotho's KLTO‑202 primary indication for ALS. The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The Australian patent adds to the company's existing intellectual property portfolio and provides a competitive advantage in the development of gene therapies for neuromuscular disorders. The KLTO-202 program, which focuses on ALS, is a key pipeline asset that could benefit from this patent protection, potentially accelerating clinical development and commercialization efforts. Investors can find the latest news and updates relating to GRML in the company's newsroom at https://nnw.fm/GRML.
This development underscores Greenland Mines' commitment to advancing its biotech division alongside its mining operations, creating a diversified portfolio that spans critical minerals and therapeutic innovations. The patent grant in Australia, a major market for biotech, signals the company's intention to protect its technology globally and paves the way for future partnerships or licensing opportunities. For more details on the full press release, visit https://nnw.fm/PVbbH.
